Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Development charge reform is needed to reduce housing costs and support new supply
-
Intuitive Machines Reports Fourth Quarter and Full-Year 2025 Financial Results
-
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
-
NIOB Exploration Work Leads to Multiple Drill Targets
-
SL Green Refinances Corporate Credit Facility
-
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
-
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
-
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
-
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
-
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
-
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
-
Electra Provides Construction Progress Update on North America’s Only Cobalt Sulfate Refinery
-
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
-
Northern York County Regional Police Becomes First in State to Deploy WrapTactics LMS, Expands BolaWrap Non-Lethal Response Capabilities
-
Mount Logan Capital Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
-
KANZHUN LIMITED Announces Shareholder Return Target Through Dividend Distribution and Extension and Upsizing of Share Repurchase Program
-
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
-
AlphaTON Capital Acquires Controlling Interest in GAMEE, Adding 119 Million Users to its Telegram Ecosystem Portfolio
-
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-
-
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
-
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
-
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
-
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
-
Mount Logan–Managed Opportunistic Credit Interval Fund (SOFIX) to Acquire $100+ Million of Assets from Yieldstreet Alternative Income Fund (YS AIF)
-
Rental Demand Softened in Late 2025 as Applications Dropped 10%, New TransUnion Analysis Shows
-
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
-
Cylinder Health appoints Terry Boch as CEO as demand grows for digestive health solutions
-
Cris & the Crew Adventures Announces Launching of Experiences and Local Partnerships in Tenerife
-
Cris & the Crew Adventures Announces Launching of Experiences and Local Partnerships in Tenerife
-
Form 8.5 (EPT/RI) - PPHE Hotel Group Ltd
-
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
-
Form 8.5 (EPT/RI) - Kore Potash Plc
-
Over 80% of Canadian Students Get Tax Refunds at H&R Block Canada; Key Filing Tips for Tax Season
-
Pizza Hut Invites Canada’s Bandwagon Fans to the Playoff Watch Party
-
Sylogist Announces Fourth Quarter and Full Year 2025 Results
-
Solo Brands, Inc. Announces Fiscal 2025 Fourth Quarter and Full Year Results
-
Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
-
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
-
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
-
Aebi Schmidt Group closed Q4 2025 with Adjusted EBITDA growing by 31% and Order Intake increasing by 46% vs Q4 2024, well positioned to accelerate order conversion and grow profitability in 2026
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-
Media Tour : Discover the New Terminal
-
Form 8.5 (EPT/RI) - CAB Payments Holdings Plc
-
Mirasol Signs LOI for the Sale of the Rubi Copper Project for US$4 Million Plus 2% NSR Royalty
-
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
-
StorageVault Announces Normal Course Issuer Bids for Common Shares and Debentures
-
Chicago Atlantic BDC, Inc. Declares $0.34 Cash Dividend for First Quarter 2026
-
VR Receives NOI Drill Permit for its New Boston Moly-Tungsten-Copper-Silver Porphyry Project in Nevada
-
Lantronix and Unusual Machines Partner to Deliver NDAA-Compliant AI-Autonomous Drone Components for U.S. Defense Programs
-
Hillman Outlines Blueprint for Strategic Growth Plans and Long-Term Financial Objectives at Inaugural Investor Day
